Pharmathene Inc (PIP) 1.86 $PIP
Market Maker Surveillance Report. COOL, BBSI, HDY, MGT, PIP, VHC, Losing Stocks With Lowest Price Friction For Tuesday, September 16th 2014
M2 - Wed Sep 17, 3:18AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4902 companies with "abnormal" market making, 2597 companies with positive Friction Factors and 2316 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. MAJESCO ENTERTAINMENT COMPANY (NASDAQ:COOL), Barrett Business Services Inc (NASDAQ:BBSI), Hyperdynamics Corp (NYSE:HDY), MGT Capital Investments Inc (NYSE:MGT), PharmAthene Inc (NYSE
IP), VirnetX Holding Corp (NYSE:VHC). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Stock to Watch: PharmAthene Down 10.5% (PIP)
Comtex SmarTrend(R) - Tue Sep 16, 10:07AM CDT
PharmAthene (AMEX IP) is one of today's worst performing low-priced stocks, down 10.5% to $1.97 on 2.1x average daily volume. PharmAthene has traded 1.5 million shares thus far today, vs. average volume of 704,000 shares per day. The stock has underperformed the Dow (-10.5% to the Dow's -0.0%) and underperformed the S&P 500 (-10.5% to the S&P's 0.1%) during today's trading.
PharmAthene Awarded Contract Of Up To $28.1 Million To Develop Next Generation Thermostable Anthrax Vaccine
PR Newswire - Wed Sep 10, 8:03AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next generation anthrax vaccine based on the Company's proprietary rPA anthrax vaccine technology platform.
New Non-Clinical Data Demonstrate SparVax® Provides Equivalent Protection In Head-To-Head Comparison With BioThrax®
PR Newswire - Tue Sep 09, 8:03AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax® anthrax vaccine program were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
PharmAthene To Present At Rodman & Renshaw And Aegis Capital Corporation 2014 Investment Conferences
PR Newswire - Mon Sep 08, 11:33AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the following investment conferences.
PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs
PR Newswire - Mon Sep 08, 9:13AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its specific expertise and resources with the objective of advancing biodefense products to be agreed to under individual product plans.
Stock to Watch: PharmAthene Up 6.4% (PIP)
Comtex SmarTrend(R) - Thu Aug 14, 10:09AM CDT
PharmAthene (AMEX IP) is one of today's best performing low-priced stocks, up 6.4% to $1.99 on 3.2x average daily volume. PharmAthene has traded 1.1 million shares thus far today, vs. average volume of 328,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.1%) and outperformed the S&P 500 (6.4% to the S&P's 0.2%) during today's trading.
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:44AM CDT
Jazz Pharmaceuticals Public Limited Company (JAZZ) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Why PharmAthene (PIP) Stock Is Soaring Today
at The Street - Mon Aug 11, 2:05PM CDT
PharmAthene (PIP) soared Monday after a Delaware court ruled SIGA Technologies (SIGA) must pay a lump sum in damages to PharmAthene.
Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages
PR Newswire - Sun Aug 10, 6:13AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that on August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and awarded to PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA Technologies, Inc.'s smallpox antiviral, Tecovirimat (formerly known as ST-246 and Arestvyr(TM)). In addition, the Court ordered SIGA to pay prejudgment interest and varying percentages of PharmAthene's reasonable attorneys' and expert witness fees.
PharmAthene Reports Second Quarter 2014 Financial And Operational Results
PR Newswire - Mon Aug 04, 3:02PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the second quarter of 2014.
PharmAthene Presents SparVax® Anthrax Vaccine Data at the New Technologies New Vaccines 2014 Conference
PR Newswire - Tue Apr 01, 1:42PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax® next-generation anthrax vaccine program were recently presented at the 8th Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's achievements in developing key analytical assays which are being employed to monitor the stability and potency of SparVax®.
PharmAthene Reports Year-End 2013 Financial And Operational Results
PR Newswire - Tue Mar 11, 3:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2013.
PharmAthene to Host Year-End 2013 Conference Call and Webcast on Tuesday, March 11, 2014
PR Newswire - Mon Mar 10, 11:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2013 will be released on Tuesday, March 11, 2014.
FTC Grants Early Termination of Hart-Scott-Rodino Act Waiting Period for Merger Transaction between Kroger and Harris Teeter
PR Newswire - Fri Jan 17, 4:34PM CST
The Kroger Co. (NYSE: KR) ("Kroger"
and Harris Teeter Supermarkets, Inc. (NYSE: HTSI) ("Harris Teeter" announced that the Federal Trade Commission today granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to the pending merger transaction between the two companies.
Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment
PR Newswire - Tue Jan 14, 11:30AM CST
Dynamic Healthcare Services, Inc. ("DHS" , a portfolio company of GMH Ventures LLC ("GMH" , announced today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive" of Clarion, PA on January 7, 2014. The terms of the acquisition were not disclosed.
New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge
PR Newswire - Fri Sep 13, 7:34AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax® next-generation anthrax vaccine program were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax® provides dose-dependent protection against lethal anthrax infection.
Investors look to Lighten Up on Shares of PharmAthene, Shares Down 6.2% (PIP)
Comtex SmarTrend(R) - Tue Sep 10, 10:15AM CDT
PharmAthene (AMEX IP) is one of today's worst performing low-priced stocks, down 6.2% to $1.97 on 1.0x average daily volume. Thus far today, PharmAthene has traded 369,000 shares, vs. average volume of 351,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.7%) and underperformed the S&P 500 (-6.2% to the S&P's 0.7%) during today's trading.
PharmAthene Inc files registration statement in connection with its merger with Theraclone Sciences Inc
M2 - Tue Sep 10, 7:25AM CDT
PharmAthene Inc (NYSE MKT IP) said on Monday that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) in connection with its merger with Theraclone Sciences Inc.
Market Maker Surveillance Report. COOL, BBSI, HDY, MGT, PIP, VHC, Losing Stocks With Lowest Price Friction For Tuesday, September 16th 2014
M2 - Wed Sep 17, 3:18AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4902 companies with "abnormal" market making, 2597 companies with positive Friction Factors and 2316 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. MAJESCO ENTERTAINMENT COMPANY (NASDAQ:COOL), Barrett Business Services Inc (NASDAQ:BBSI), Hyperdynamics Corp (NYSE:HDY), MGT Capital Investments Inc (NYSE:MGT), PharmAthene Inc (NYSE
IP), VirnetX Holding Corp (NYSE:VHC). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . Stock to Watch: PharmAthene Down 10.5% (PIP)
Comtex SmarTrend(R) - Tue Sep 16, 10:07AM CDT
PharmAthene (AMEX
IP) is one of today's worst performing low-priced stocks, down 10.5% to $1.97 on 2.1x average daily volume. PharmAthene has traded 1.5 million shares thus far today, vs. average volume of 704,000 shares per day. The stock has underperformed the Dow (-10.5% to the Dow's -0.0%) and underperformed the S&P 500 (-10.5% to the S&P's 0.1%) during today's trading. PharmAthene Awarded Contract Of Up To $28.1 Million To Develop Next Generation Thermostable Anthrax Vaccine
PR Newswire - Wed Sep 10, 8:03AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next generation anthrax vaccine based on the Company's proprietary rPA anthrax vaccine technology platform.
New Non-Clinical Data Demonstrate SparVax® Provides Equivalent Protection In Head-To-Head Comparison With BioThrax®
PR Newswire - Tue Sep 09, 8:03AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax® anthrax vaccine program were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
PharmAthene To Present At Rodman & Renshaw And Aegis Capital Corporation 2014 Investment Conferences
PR Newswire - Mon Sep 08, 11:33AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the following investment conferences.
PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs
PR Newswire - Mon Sep 08, 9:13AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its specific expertise and resources with the objective of advancing biodefense products to be agreed to under individual product plans.
Stock to Watch: PharmAthene Up 6.4% (PIP)
Comtex SmarTrend(R) - Thu Aug 14, 10:09AM CDT
PharmAthene (AMEX
IP) is one of today's best performing low-priced stocks, up 6.4% to $1.99 on 3.2x average daily volume. PharmAthene has traded 1.1 million shares thus far today, vs. average volume of 328,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.1%) and outperformed the S&P 500 (6.4% to the S&P's 0.2%) during today's trading. Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:44AM CDT
Jazz Pharmaceuticals Public Limited Company (JAZZ) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Why PharmAthene (PIP) Stock Is Soaring Today
at The Street - Mon Aug 11, 2:05PM CDT
PharmAthene (PIP) soared Monday after a Delaware court ruled SIGA Technologies (SIGA) must pay a lump sum in damages to PharmAthene.
Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages
PR Newswire - Sun Aug 10, 6:13AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that on August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and awarded to PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA Technologies, Inc.'s smallpox antiviral, Tecovirimat (formerly known as ST-246 and Arestvyr(TM)). In addition, the Court ordered SIGA to pay prejudgment interest and varying percentages of PharmAthene's reasonable attorneys' and expert witness fees.
PharmAthene Reports Second Quarter 2014 Financial And Operational Results
PR Newswire - Mon Aug 04, 3:02PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the second quarter of 2014.
PharmAthene Presents SparVax® Anthrax Vaccine Data at the New Technologies New Vaccines 2014 Conference
PR Newswire - Tue Apr 01, 1:42PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax® next-generation anthrax vaccine program were recently presented at the 8th Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's achievements in developing key analytical assays which are being employed to monitor the stability and potency of SparVax®.
PharmAthene Reports Year-End 2013 Financial And Operational Results
PR Newswire - Tue Mar 11, 3:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2013.
PharmAthene to Host Year-End 2013 Conference Call and Webcast on Tuesday, March 11, 2014
PR Newswire - Mon Mar 10, 11:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2013 will be released on Tuesday, March 11, 2014.
FTC Grants Early Termination of Hart-Scott-Rodino Act Waiting Period for Merger Transaction between Kroger and Harris Teeter
PR Newswire - Fri Jan 17, 4:34PM CST
The Kroger Co. (NYSE: KR) ("Kroger"
and Harris Teeter Supermarkets, Inc. (NYSE: HTSI) ("Harris Teeter" announced that the Federal Trade Commission today granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to the pending merger transaction between the two companies. Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment
PR Newswire - Tue Jan 14, 11:30AM CST
Dynamic Healthcare Services, Inc. ("DHS"
, a portfolio company of GMH Ventures LLC ("GMH" , announced today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive" of Clarion, PA on January 7, 2014. The terms of the acquisition were not disclosed. New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge
PR Newswire - Fri Sep 13, 7:34AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax® next-generation anthrax vaccine program were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax® provides dose-dependent protection against lethal anthrax infection.
Investors look to Lighten Up on Shares of PharmAthene, Shares Down 6.2% (PIP)
Comtex SmarTrend(R) - Tue Sep 10, 10:15AM CDT
PharmAthene (AMEX
IP) is one of today's worst performing low-priced stocks, down 6.2% to $1.97 on 1.0x average daily volume. Thus far today, PharmAthene has traded 369,000 shares, vs. average volume of 351,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.7%) and underperformed the S&P 500 (-6.2% to the S&P's 0.7%) during today's trading. PharmAthene Inc files registration statement in connection with its merger with Theraclone Sciences Inc
M2 - Tue Sep 10, 7:25AM CDT
PharmAthene Inc (NYSE MKT
IP) said on Monday that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) in connection with its merger with Theraclone Sciences Inc. 
